Workflow
卫宁健康:2024年报及2025年一季报点评经营质量提升,WiNEX进入快速交付期-20250521

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 11.28 CNY for 2025 [2][7]. Core Views - The company is experiencing a short-term performance pressure due to deferred downstream demand, but it is expected to improve as the WiNEX product enters a rapid delivery phase [7]. - The company has achieved a significant market share of 13.4% in the core hospital system market in China, ranking first [7]. - The company is focusing on enhancing its operational quality, with a notable increase in cash flow from operating activities, which grew by 120.5% year-on-year [7]. Financial Summary - Total revenue for 2024 is projected at 2,782 million CNY, a decrease of 12.0% year-on-year, with a net profit of 88 million CNY, down 75.4% year-on-year [3][7]. - For 2025, the company expects revenue to increase to 3,147 million CNY, reflecting a growth rate of 13.1%, and net profit to rise significantly to 384 million CNY, indicating a growth rate of 336.7% [3][7]. - The company’s earnings per share (EPS) is projected to be 0.04 CNY in 2024, increasing to 0.17 CNY in 2025 [3][7]. Business Development - The company is actively developing its WiNEX product line and has made significant investments in AI applications, with R&D expenses accounting for 20.2% of revenue [7]. - The company has established a digital health application ecosystem, with subsidiaries generating revenues of 1.6 million CNY, 2.1 million CNY, and 1.9 million CNY respectively in 2024 [7]. - The company is enhancing its international presence, exemplified by the successful implementation of a project at the Macau Concordia Hospital [7].